Chest pain suggestive of acute coronary syndrome (ACS) is a common cause of presentation to emergency departments and contributes to 20-37% of medical admissions 1, 2 . In up to 90% of patients presenting with suspected ACS, the diagnosis is subsequently ruled out, generally after a period of observation and a series of investigations that lead to substantial health-care costs 3, 4 . Diagnostic pathways based on the 12-lead electrocardiogram (ECG) and on older-generation blood biomarkers missed ACS in 2-5% of patients, potentially resulting in inappropriate discharge from hospital [5] [6] [7] . Modern blood biomarkers, such as fifth-generation tropo nins measured with a high-sensitivity assay, improve the detection of ACS, but can have low specificity, which leads to unnecessary further investigations 8 . For example, hearttype fatty acid-binding protein is a novel biomarker of myocardial ischaemia that provides incremental value when used in combination with troponins measured with a high-sensitivity assay 9 . However, even with modern biomarkers, ACS cannot reliably be ruled out from a single early blood sample, and current guidelines recommend serial sampling that necessitates prolonged observation 10 . Furthermore, evidence of the diagnostic value of novel cardiac bio markers in patients with unstable angina is insufficient; these patients, by definition, have no elevation of conventional serum markers 10, 11 . Cardiac imaging can complement patient history, ECG, and cardiac biomarkers for timely identification or exclusion of ACS (FIG. 1) . When appropriately used, imaging can reduce the rate of missed diagnoses and guide the management of those patients with confirmed ACS. The most commonly used noninvasive techniques are discussed in this Review, including echocardio graphy and stress echocardiography, computed tomography coronary angiography (CTCA), myocardial perfusion scintigraphy (MPS), positron emission tomography (PET), and cardiovascular magnetic resonance (CMR) imaging. An overview of the relative strengths and weaknesses of each of these modalities in the assessment of patients with acute chest pain is given in TABLE 1.
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Transthoracic echocardiography
The ESC guidelines for the management of suspected ACS endorse bedside standard 2D transthoracic echocardiography (2D-TTE) as the first-line imaging technique (class 1c evidence) for patients with acute chest pain 12 (TABLE 2). In the ESC guidelines for the management of ST-segment elevation myocardial infarction (STEMI), 2D-TTE is recommended for the diagnosis of other causes of chest pain, such as pulmo nary embolus, dissec tion of the ascending aorta, or pericardial effusion 13 . Similarly, the ACC Foundation ' Appropriate use criteria for echocardiography', published in 2011, rate the role of 2D-TTE in suspected ACS as 'appropriate' (REF. 14) .
In clinical practice, 2D-TTE can be helpful in patients with suspected STEMI if a diagnosis cannot be made from the patient's history and ECG. In these circumstances, early 2D-TTE can be used to detect regional wall-motion abnormalities and assist the decision for invasive assessment and primary percutaneous coronary intervention (FIG. 2) . Several studies have demonstrated the incremental value of 2D-TTE over the ECG in the assessment of patients with suspected ACS [15] [16] [17] [18] [19] [20] [21] [22] .
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In a study of 280 patients with suspected ACS on the role of echocardiography in patients with an equivocal ECG, echocardiography had a sensitivity of 71%, a speci ficity of 91%, and a negative predictive value of 73% for diagnosing ACS 7 . In the ischaemic cascade, regional wall-motion abnormalities precede ECG changes and can be detected even if the patient presents many hours after an event 18, 23 (FIG. 3) . However, the presence of regional wall-motion abnormalities is not only associated with myocardial ischaemia, but also with previous myocardial infarction (MI), focal myocarditis, left bundle branch block, and several cardio myopathies, posing diagnostic challenges. In some patients, a poor acoustic window because of body habitus or lung diseases might limit the acquisition of diagnostically useful images 24 . Novel 2D-TTE methods offer additional information over regional wall-motion abnormalities alone. Before contracting during the ejection phase, the ischaemic myocardial segments tend to stretch as the intra ventricular pressure rises steeply during the iso volumetric contraction phase 25, 26 . Strain imaging can identify this process in patients with suspected ACS [27] [28] [29] . In a study that used a cut-off value for global peak systolic longitudinal strain of −20%, strain imaging had 93% sensitivity and 78% specificity for the diagnosis of myo cardial ischaemia 27 . Another study showed a strong correlation between segmental strain imaging and coro nary stenosis on invasive coronary angio graphy in patients with no apparent regional wall-motion abnormality 28 . Furthermore, absence, or a shorter duration, of early systolic lengthening on strain imaging accurately identi fied patients with non-ST-segment elevation myocardial infarction (NSTEMI) even in those with minimal myocardial damage 30 . In this study, the duration of early systolic lengthening was more prolonged in patients with coronary occlusions than in those without occlusions (86 ± 45 versus 63 ± 31 ms; P <0.01), and showed good correlation with final infarct size (r = 0.67, P <0.001). Figure 1 | Algorithm for the management of patients with suspected acute coronary syndrome (ACS). Use of cardiac imaging is dependent on resting electrocardiogram (ECG) and troponin level measured by high-sensitivity assay (hs-Tn). Adapted from ESC guidelines 12 . CMR, cardiovascular magnetic resonance; CTCA, computed tomography coronary angiography; Echo, echocardiography; MPS, myocardial perfusion scintigraphy; PPCI, pri mary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
Key points

Contrast echocardiography
Contrast agents can improve endocardial detection for the assessment of regional wall-motion abnormalities in TTE. Real-time myocardial contrast echocardiography extends the evaluation of wall-motion abnormalities by assessing myocardial perfusion. Importantly, initial concerns over the safety of ultrasound contrast agents (SonoVue ® , Bracco Imaging SpA, Italy, and Luminity ® , Lantheus Medical Imaging, USA) proved to be unfounded and the agents are now considered safe in patients with chest pain and suspected ACS 31 . Several studies have shown that the use of contrast echocardiography can accurately identify patients with ACS and contribute to prognostication. In a study of 957 patients presenting to the emergency department with chest pain, normal wall thickening on contrast echo cardiography was associated with a low incidence of future adverse events, whereas both abnormal wall thickening and a myocardial perfusion defect suggestive of ischaemia were associated with a high incidence of events 23 . In this study, the negative predictive value for contrast echocardiography was extremely high, at 99-100%. However, the positive predictive value was very poor in the presence of previous MI (in the range of 2.9-14.0% between the four quartiles, which were assigned on the basis of the time interval between the last episode of chest pain and contrast echocardio graphy). In another study, multivariate logistic regression analysis was used to compare myocardial contrast echocardiography, Thrombolysis In Myocardial Infarction (TIMI) risk score, abnormal ECG, and troponin T levels in 100 patients and the results showed that myocardial contrast echocardiography was the strongest predictor of ACS, and the measured perfusion defect size correlated with the ejection fraction at 4 weeks follow-up (r = −0.79, P <0.001) 32 . Two other studies have also shown that myocardial contrast echocardiography can provide incremental mid-term (30 days) and long-term (2 years) prognostic information over a modified TIMI score 33, 34 . Myocardial contrast echocardiography in the emergency room can be cost-effective, with a saving of US$900 per patient compared with usual care 35 . Table 1 • Not available at all times • Expertise for comprehensive imaging in this setting is not widely available • Patients with claustrophobia, fast heart rates, severe renal impairment, high burden of ventricular ectopics, and ferromagnetic implants might not be eligible for stress CMR • Adequate renal function is required (eGFR >30 ml/min/1.73 m 2 ), otherwise there is a risk of nephrogenic systemic fibrosis CMR, cardiovascular magnetic resonance; CTCA, computed tomography coronary angiography; Echo, echocardiography; EET, exercise electrocardiography test; EGE, early gadolinium enhancement; IMH, intramyocardial haemorrhage; LGE, late gadolinium enhancement; MCE, myocardial contrast echocardiography; MPS, myocardial perfusion scintigraphy; MVO, microvascular obstruction; RCT, randomized, controlled trial; TTE, transthoracic echocardiography.
Echocardiography methods under development include antibody-coated microbubbles to image selectins, which are adhesion molecules that are expressed by the injured endothelium in acute ischaemia and persist for several hours after the acute event, providing an 'ischaemic memory' . However, these antibodycoated microbubbles have been evaluated only in animal models 36 .
Stress echocardiography
The role of exercise and pharmacological stress echocardiography in the assessment of suspected ACS (FIG. 4) has been studied extensively 31, [37] [38] [39] [40] [41] [42] [43] . The use of stress echocardiography is advocated in the ESC guidelines on suspected ACS (class I, level A evidence) 12 , and is categor ized as appropriate in US guidelines on suspected ACS 14 . In both guidelines, the use of stress echocardio graphy is mainly recommended for patients with no resting chest pain, normal ECG findings, no elevation in troponin levels, and a low risk score.
The diagnostic accuracy of stress echocardio graphy was evaluated in a study of 503 patients with acute chest pain who underwent exercise stress echocardiography and exercise MPS for the detection of coronary artery disease (CAD) 38 . Stress echocardio graphy had similar sensitivity to stress MPS (85% versus 86%), with slightly, but significantly, greater specificity (95% versus 90%). The sensitivity of exercisetolerance testing was significantly lower (43%) than that of stress echocardio graphy, although the specificity was simi lar (95%). In a real-world study to assess the feas ibility and safety of stress echocardiography in 839 consecutive patients presenting to chest pain units, 811 (96.7%) patients had technically successful stress echocardio graphy with no major complications 41 . At 1-year follow-up, hard event rates (all-cause mortal ity and acute MI) were 0.5% in the normal stress echocardio graphy group versus 6.6% in the abnormal stress echocardio graphy group. In multi variate regression analysis, only abnormal stress echocardiography (HR 4.08, 95% CI 2.15-7.72, P <0.001) and advancing age (HR 1.78, 95% CI 1.39-2.37, P <0.001) predicted MI and death. A prospective, double-blind, multicentre study of dobutamine stress echocardio graphy in 377 low-risk patients presenting to the emergency department with acute chest pain showed a 6-month incidence of composite cardiac events of 14/351 (4%) in patients with a negative dobutamine stress echocardiography and 8/26 (30.8%) in patients with positive dobutamine stress echocardiography (P <0.0001) 42 . In a head-to-head comparison of stress echocardio graphy and ECG-based exercise-tolerance testing, stress echocardiography was superior to exercise-tolerance testing in stratifying patients as low risk (77% versus 33%; P <0.0001). In addition, fewer of the patients who underwent stress echocardiography required further tests than those who underwent exercise-tolerance testing (3% versus 47%; P <0.0001), and stress echocardiography was more cost-effective than exercise-tolerance testing (UK£366.63 versus £515.48; P = 0.004) 39 . In another study of 199 patients with acute-onset chest pain presenting to the emergency department and randomly assigned to exercise-tolerance testing or stress echocardiography, the cost-effectiveness was similar, but the event rate was significantly higher in patients who underwent exercise-tolerance testing than in those who underwent stress echocardiography (11% versus 0%; P = 0.004) 43 .
Computed tomography coronary angiography
The use of CTCA is rapidly expanding and recommendations for the use of this imaging test are included in several relevant guidelines. The ACC Foundation ' Appropriate use criteria for cardiac computed tomography' have endorsed CTCA as an appropriate test in the context of acute chest pain with normal or nondiagnostic ECG, and normal or equivocal biomarkers in the groups determined pretest to have low or intermediate likelihood of an ACS 44 . CTCA is also endorsed by the ACC Foundation for the evaluation of suspected coronary anomalies in this setting. Similarly, the ESC guidelines on suspected ACS recommend CTCA (class IIa, level B evidence) as an alternative to invasive coronary angiography to exclude ACS or other causes (TABLE 2) .
High-quality CTCA is feasible with multidetector CT scanners acquiring ≥64 slices, and these scanners are now widely available, including in many emergency departments 45 . In a meta-analysis of nine studies [46] [47] [48] [49] [50] [51] [52] [53] [54] involving 1,559 patients with symptoms suggestive of ACS and an initial nondiagnostic ECG, the pooled sensitivity, specificity, and positive and negative predictive values for 64-slice CTCA for major cardiovascular events at 30 days were 93.3%, 89.9%, 48.1%, and 99.3%, respectively 55 . Four randomized, controlled clinical trials have incorporated CTCA into an early evaluation strategy in patients with suspected ACS presenting to the emergency department and have compared this test with usual care [56] [57] [58] [59] . A meta-analysis of these trials involving 3,266 patients determined pretest to have a low-to-intermediate likelihood of ACS showed that incorpor ating CTCA shortened the hospital stay. However, the pooled weighted incidence of invasive coronary angio graphy was 8.4% in the CTCA group versus 6.3% in the standard investigation group (P = 0.03) -a relative increase of invasive coronary angiography rates of 33% 60 . Whether the observed increase in invasive procedures leads to improved patient outcome or decreases the need for future testing is unknown. A long-term outcome study published in 2014 to assess the use of CTCA in 196 patients with suspected ACS and a median follow-up of 47.4 months showed an excellent prognosis if CTCA was negative (1% readmitted with chest pain; 0% revascularization, ACS, or death) 61 . In addition to coronary imaging, coronary artery calcium scoring has also been shown to have a high negative predictive value of 99% in patients presenting with acute chest pain 62 . However, the use of coronary artery calcium scoring alone in this study missed two patients (1.5%) with obstructive CAD. In another study of 1,049 patients, addition of coronary artery calcium scoring analysis to CTCA did not help to predict 30-day cardio vascular events 63 . Contrast-enhanced CT can be used to assess myocardial perfusion. A retrospective study of 158 consecutive patients who underwent ungated contrastenhanced CT in the emergency department to rule out other causes of chest pain (mainly pulmonary embolus) showed high sensitivity (93%) and specificity (87%) of perfusion CT to detect acute MI (defined by a rise in troponin levels) 64 . Similarly, a subgroup analysis of the ROMICAT trial 65 that evaluated the role of CTCA in acute chest pain showed that the assessment of myocardial perfusion and regional wall-motion abnormalities by CT improved the detection of ACS Nature Reviews | Cardiology (area under the curve 0.88 versus 0.79; P = 0.02).
In patients with a nondiagnostic ECG and equivocal cardiac biomarkers, current evidence shows that CTCA has a high negative predictive value for excluding ACS in low-to-intermediate likelihood groups, and can facilitate triage decisions and reduce lengths of hospital stay in patients with suspected ACS. In a multi centre, ran domized, controlled trial of 749 patients, costs of care were 38% lower using CTCA compared with standard care 57 . Also, in the same study, time to diagnosis was signifi cantly shorter for CTCA versus MPS (2.9 h, 95% CI 2.1-4.0 h versus 6.3 h, 95% CI 4.2-19.0 h; P <0.0001) 57 .
Radionuclide imaging MPS is the most established method for assessment of ischaemia and viability 66, 67 . A full MPS study consists of imaging after both stress and rest injections of thallium-201 or technetium-99m labelled tracers, with the resting study showing myocardial scar and the stress-induced defects indicating inducible hypoperfusion, suggesting myocardial ischaemia.
Among the currently available techniques in the acute setting, MPS has the strongest prognostic data. MPS is endorsed by the US ' Appropriate use criteria for cardiac radionuclide imaging' (REF. 68 ) and the ESC 12 guidelines as an appropriate test in suspected ACS when diagnosis was not confirmed by ECG and biomarkers (TABLE 2) . Many observational studies have assessed the diag nostic and prognostic performance of rest MPS in the acute setting [69] [70] [71] [72] [73] [74] [75] [76] [77] . In a pooled analysis of 2,465 patients presenting with recent (<6 h) pain, the sensitivity of detecting MI by rest MPS was 90%, with a specificity of 80% and a negative predictive value of 99% 78 . The ERASE trial 79 was a large (n = 2,475) multicentre, randomized trial in which MPS was compared with usual care and showed a 14% reduction in hospital admission and an estimated cost-saving of US$60 to $72 per patient with the incorpor ation of MPS. Several prospective, randomized trials have also shown that resting MPS is cost-effective, and that the use of resting MPS improves the triage of patients presenting with acute chest pain [80] [81] [82] [83] . In the short term, 30-day cardiac event rates (acute MI, death, or revascularization) are 3% with normal MPS compared with 10-30% with abnormal MPS 75, 80 . Finally, an observational study of 1,187 consecutive patients showed excellent 1-year outcomes in patients with normal MPS compared with those with abnormal MPS (0% MI or death versus 11% MI and 8% cardiac death; P <0.001) 73 . Although rest MPS is an excellent rule-out test, the sensitivity of this test in patients who no longer have chest pain is low 84 . Another limitation is that rest MPS cannot be used to distinguish between acute and chronic MI 85 , as both appear as hypoperfused areas. After the initial chest pain has settled, stress-rest MPS to detect inducible hypoperfusion is more accurate and has greater prognostic value than rest MPS [86] [87] [88] . The stress study is usually performed after a normal resting study, which can delay discharge from hospital; however, the stress study can be performed after discharge in otherwise low-risk patients. Initial stress MPS in low-risk patients is safe and has similar performance to rest MPS alone 89 . MPS techniques developed in the past decade allow myocardial metabolism to be imaged. In ischaemic memory imaging, prolonged functional and/or biochemical alterations after an episode of severe myocardial ischaemia are detected. Myocardial ischaemia leads to a shift from aerobic fatty acid to anaerobic glucose metabolism 90 . Even when myocardial perfusion is restored and ischaemia has resolved, the return to fatty acid metabolism can take ≥12 h 91 . This metabolism shift can be imaged using the fatty acid analogue β-methyl-p-[ F-fluorodeoxyglucose (FDG) is a glucose analogue tracer that is used in PET imaging to measure glucose utilization. The tracer accumulates in normal and ischaemic (viable) myocardium; however, under fasting conditions, FDG uptake is suppressed in normal myocardium and is accumulated in the ischaemic region 91 . Therefore, for FDG-PET ischaemic memory imaging, FDG is administered after a fast of ≥6 h or after an overnight fast. Flurpiridaz F-18 is a novel tracer in phase III clinical trials that has demonstrated increased image quality, with higher contrast and resolution than current PET tracers 94 . However, the value of flurpiridaz F-18 in patients with suspected ACS remains unknown.
Hybrid imaging classically involves the combination (or fusion) of an anatomical (CTCA) and a functional test (SPECT, PET, CMR). Hybrid imaging is superior in determining the presence of functionally significant CAD (stenosis ≥70% with ≥10% myocardial ischaemic burden) compared with either of the individual techniques 95 . The first reports of PET-CT [96] [97] [98] and SPECT-CT [99] [100] [101] have suggested a role for hybrid imaging in detecting functionally significant CAD, but further evaluation in patients with ACS is required. In addition, the availability of hybrid imaging is currently limited to a small number of centres with appropriate expertise and equipment.
Cardiovascular magnetic resonance CMR has an emerging role in the assessment and manage ment of patients with ACS, in particular those who are clinically stable. CMR provides structural and functional assessment of regional myocardial motion and thickening, rest and stress perfusion, myocardial oedema, microvascular obstruction, and intramyocardial haemorrhage 102 . available, might be appropriate to detect coronary anoma lies. Current ESC guidelines highlight in particular the use of CMR to detect myocarditis and assess viability and perfusion defects in patients with suspected ACS 12 . The ESC guidelines on the management of suspected NSTEMI also recommend stress CMR (class I, level A evidence) in patients without recurrent pain, normal ECG, negative troponin level, and a low (≤108) Global Registry of Acute Coronary Events (GRACE) risk score 12 (TABLE 2) .
A study published in 2004 showed that CMR was feas ible and safe in 72 patients with recent non-STsegment elevation ACS 104 . CMR within 3 days of the event had 96% sensitivity and 83% specificity for the detection of signifi cant CAD (stenosis ≥70%) defined by invasive angio graphy. CMR was also more accurate than the TIMI risk score (P <0.001). In a study of 161 patients presenting to the emergency department within 12 h of symptoms suggest ive of ACS, but without ST-segment elevation on initial ECG, the diagnostic performance of CMR was evaluated using cine imaging for left ventricular function, resting first-pass perfusion, and late gadolinium enhancement 105 . Total imaging time was 38 min and patients were absent from the emergency department for <1 h. Although the sensitivity and specificity for the diagnosis of ACS, as defined by troponin I level and invasive angiography, for this CMR protocol were only 84% and 85%, respectively, CMR added incremental value over clinical parameters.
Myocardial oedema develops before ischaemic necrosis or even troponin release 106 . The oedema can persist even when ECG changes and myocardial dysfunction have resolved 107 (FIG. 3) , and can persist for up to 1 month 108 . A study in which oedema-sensitive T2-weighted imaging (T2W-imaging) was added to the CMR protocol used in previous reports showed increased specificity, positive predictive value, and overall accuracy (96%, 85%, and 93%, respectively) compared with the conventional CMR protocol, whereas sensitivity remained at 85% 109 . In addition, in this study, the use of oedema-sensitive T2W-imaging accurately identified all patients with acute MI, often before cardiac biomarkers were elevated. A study of 135 low-risk patients presenting to the emergency department with chest pain showed that none of the patients with a normal adeno sine CMR study had a subsequent diagnosis of CAD or an adverse outcome after 1 year 110 . In the same study, the sensitivity of stress CMR was 100%, with a specificity of 93% for predicting adverse outcomes during a 1-year follow-up period. In two similar separate studies evaluating 192 patients who received adenosine stress and rest CMR, none of the patients with normal CMR had clinical events during 9 months of follow-up 111, 112 . Finally, in a randomized trial to evaluate the cost-effectiveness of stress CMR in 110 intermediate-risk and high-risk patients with ACS, stress CMR led to a cost-saving of >20% compared with standard inpatient care (US$3,101 versus $4,742; P = 0.004). The decrease of medical-care costs was a result of the reductions in coronary artery revascular ization, readmissions to hospital, and further cardiac testing, without an increase in postdischarge ACS at 90 days 113 . Emerging CMR methods for ACS imaging include parametric mapping techniques. T1-mapping can be used to quantify the extent and severity of acute ischaemic injury (FIG. 5) . In an early study, noncontrast T1-maps had 96% sensitivity and 91% specificity for detecting acute MI 114 . In a subsequent report, T1-mapping was superior to T2W-imaging in detecting NSTEMI (area under the curve 0.91 ± 0.02 versus 0.81 ± 0.04; P = 0.004) 115 . T1-mapping is also superior to T2W and late gadolinium enhancement imaging in detecting acute myocarditis, which is one of the main differential diagnoses in patients with acute chest pain 116, 117 .
Value of noninvasive imaging tests
Whether noninvasive imaging improves clinical outcome in patients presenting with possible ACS, and which imaging strategy provides the best results, remains unknown. In a retrospective analysis of privately insured patients in the USA who presented with chest pain but no evidence of MI by 24 h, early testing using CTCA, stress echocardiography, MPS, and exercise ECG led to higher rates of cardiac catheterization and revascular ization, but no reduction in cardiac events compared with conservative management 118 . Notably, stress echocardiography did not lead to a rise in invasive downstream investigation. CMR was not included in this study, highlighting the need for further large, prospective trials that include all contemporary imaging modalities 118 . 
